ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 만성폐쇄성폐질환(COPD) 치료 기기 시장 규모는 2025-2032년 예측 기간 동안 CAGR 6.35%로 성장할 것으로 예상됩니다. 시장은 여러 가지 중요한 요인에 의해 크게 성장할 것으로 예상됩니다. 만성폐쇄성폐질환(COPD)의 유병률 증가, 고령화, 흡연, 대기오염의 증가로 인해 효과적인 호흡 보조장치에 대한 수요가 증가하고 있습니다. 또한, 인식의 향상과 검진 프로그램은 조기 진단과 조기 치료로 이어져 흡입기, 산소발생기, 분무기 등의 장비에 대한 수요를 더욱 증가시키고 있습니다. 시장의 주요 기업들도 제품 개발에 투자하여 환자의 순응도를 높이고 재택 치료를 가능하게 하는 휴대용, 스마트, 사용자 친화적인 기술을 도입하고 있으며, 이는 2025-2032년 예측 기간 동안 COPD 치료 기기 시장의 강력한 성장을 촉진하고 있습니다.
만성폐쇄성폐질환(COPD) 치료제 시장 역학
Australian Institute of Health and Welfare가 제공한 최신 데이터에 따르면, 2022년 호주에서 약 850만 명(34%)이 만성 호흡기질환을 앓고 있는 것으로 추정됩니다.
또한, Global Burden of Disease(2023)의 최신 데이터에 따르면, 전 세계 인구 약 20명 중 1명이 만성 호흡기질환을 앓고 있습니다.
또한, 세계보건기구(WHO)(2023)의 최근 자료에 따르면 흡연은 만성폐쇄성폐질환(COPD)의 주요 원인으로, 호흡곤란을 유발하는 흔한 폐질환으로 연간 300만 명 이상의 목숨을 앗아가는 것으로 나타났습니다. 약 3억 9,200만 명이 COPD를 앓고 있으며, 약 75%는 중저소득 국가에 거주하고 있습니다. 고소득 국가에서는 흡연이 COPD 환자의 70% 이상이 흡연을 원인으로 꼽았습니다. 흡연과 환경적 요인으로 인한 호흡기질환 환자가 증가함에 따라 분무기, 흡입기 등 COPD 치료 기기에 대한 수요가 증가하고 있습니다. 분무기는 효과적인 증상 완화 및 질병 관리를 위해 폐에 직접 약물을 공급하는 데 중요합니다. 또한, 건조 분말 흡입기도 폐에 약물을 공급하기 위해 사용되어 COPD 치료 기기 시장 전체를 확대시키고 있습니다.
또한, 주요 시장 기업의 제품 개발 활동이 증가함에 따라 COPD 치료 기기 시장이 더욱 활성화되고 있습니다. 예를 들어, 2024년 5월 Medline은 자사의 호흡기 치료 포트폴리오에 새롭게 추가된 Hudson RCI TurboMist small volume nebulizer를 발표했으며, TurboMist는 단 3분 만에 약물을 투약할 수 있습니다.
이와 같이, 상기 요인은 예측 기간 동안 COPD 치료 기기 시장을 견인할 것으로 예상됩니다.
그러나 제품 승인에 대한 엄격한 정부 규제와 흡입기 관련 환경적 우려는 최종사용자 기반을 제한할 수 있으며, 만성폐쇄성폐질환(COPD) 치료 기기의 성장을 제한하는 주요 요인으로 작용할 수 있습니다.
북미가 만성폐쇄성폐질환(COPD) 치료 기기 시장 전체를 장악할 것으로 예상
모든 지역 중 북미가 2024년 만성폐쇄성폐질환(COPD) 치료 기기 시장을 주도할 것으로 예상됩니다. 만성폐쇄성폐질환(COPD) 유병률 증가, 대기오염, 공기 중 미립자, 화학제품, 가스, 매연, 산업화학제품, 분진 노출과 같은 동반 질환의 증가, 미국 내 젊은 층의 담배 소비 증가 등이 COPD 치료 기기 시장의 성장을 촉진하는 요인으로 작용하고 있습니다. 또한, 이 지역의 주요 기업의 존재는 2025-2032년 예측 기간 동안 만성폐쇄성폐질환(COPD) 치료 기기 시장의 지속적인 확장과 기술 혁신을 촉진할 것으로 예상됩니다.
미국 질병예방통제센터(2024)의 자료에 따르면, 2022년 18세 이상 미국 성인의 약 11.6%가 담배를 피우고 있으며, 이는 약 2,880만 명에 해당합니다. 이 자료에 따르면, 1,600만 명 이상의 미국인이 흡연과 관련된 질병을 앓고 있습니다. 흡연은 COPD 발병과 관련된 주요 위험 요소입니다.
세계의 만성폐쇄성폐질환(COPD) 치료 기기 시장에 대해 조사 분석했으며, 시장 규모와 예측, 지난 3년간의 제품/서비스 개발 현황, 주요 기업, 시장 기회 등의 정보를 전해드립니다.
목차
제1장 만성폐쇄성폐질환(COPD) 치료 기기 시장 보고서 소개
제2장 만성폐쇄성폐질환(COPD) 치료 기기 시장 주요 요약
시장 개요
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 만성폐쇄성폐질환(COPD) 치료 기기 시장의 주요 요인 분석
만성폐쇄성폐질환(COPD) 치료 기기 시장 촉진요인
만성폐쇄성폐질환(COPD) 치료 기기 시장 억제요인과 과제
만성폐쇄성폐질환(COPD) 치료 기기 시장 기회
제6장 만성폐쇄성폐질환(COPD) 치료 기기 시장 Porter's Five Forces 분석
제7장 만성폐쇄성폐질환(COPD) 치료 기기 시장 평가
제품 유형별
흡입기
네블라이저
최종사용자별
병원·진료소
재택 케어 환경
기타
지역
북미
유럽
아시아태평양
기타 지역
제8장 만성폐쇄성폐질환(COPD) 치료 기기 시장 : 기업과 제품 개요
Koninklijke Philips N.V.
Omron Healthcare, Inc.
Aerogen
GF Health Products, Inc.
BMC Medical Co., Ltd.
Medtronic
Trudell Medical International
Novartis AG
AstraZeneca
Lupin
Zydus Cadila
Teva Pharmaceutical Industries Ltd
Terumo Corporation
Cipla Inc.
Microlife Corporation
Honsun
Promed Technology Co. Limited
HELTMAN Medikal A.S.
Pneuma Respiratory
Lepu Medical Technology(Beijing) Co., Ltd.
제9장 KOL의 견해
제10장 프로젝트 접근법
제11장 DelveInsight 소개
제12장 면책사항, 문의
ksm
영문 목차
영문목차
Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, and Others] and Nebulizers [Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), End-User (Hospitals & Clinics, Homecare Settings, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing prevalence of chronic obstructive pulmonary disorder, high rate of tobacco smoking and air pollution, increasing awareness and screening programs, and increase in product development activities among the key market players.
The chronic obstructive pulmonary disease treatment devices market is estimated to grow at a CAGR of 6.35% during the forecast period from 2025 to 2032. The market for COPD treatment devices is expected to grow significantly due to several key factors. The increasing prevalence of chronic obstructive pulmonary disease, largely driven by aging populations, tobacco smoking, and rising air pollution, is creating a higher demand for effective respiratory support devices. Additionally, growing awareness and screening programs are leading to earlier diagnosis and treatment, further boosting the need for devices such as inhalers, oxygen concentrators, and nebulizers. Key market players are also investing in product development, introducing portable, smart, and user-friendly technologies that enhance patient compliance and enable home-based care, together driving strong growth in the COPD treatment devices market during the forecast period from 2025 to 2032.
According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.
Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately 1 in 20 people globally suffered from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people had COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases. As the cases of respiratory disorders rise, driven largely by smoking and environmental factors, there is a heightened need for COPD treatment devices such as nebulizers and inhalers. Nebulizers are critical in delivering medication directly to the lungs for effective symptom relief and disease management. Further, dry powder inhaler devices are used to deliver medication to the lungs, thereby escalating the overall market of COPD treatment devices.
Additionally, the increase in product development activities among the key market players is further boosting the market for COPD treatment devices. For instance, in May 2024, Medline announced the latest addition to its respiratory care portfolio, the Hudson RCI TurboMist small volume nebulizer is designed to be the fastest small volume nebulizer on the market. TurboMist delivered medication treatments in as little as three minutes.
Thus, the factors mentioned above are expected to boost the market for COPD treatment devices during the forecast period.
However, the stringent government regulations for product approval and environmental concerns associated with inhalers may limit their end-user base, thus acting as key constraints limiting the growth of the chronic obstructive pulmonary disease treatment devices.
Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, and Others] and Nebulizers [Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), End-User (Hospitals & Clinics, Homecare Settings, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of chronic obstructive pulmonary disease treatment devices, the metered dose inhaler category is expected to have a significant revenue share in the year 2024. Metered dose inhalers are a widely preferred delivery system for managing chronic obstructive pulmonary disease because of their portability, ease of use, and ability to deliver precise doses of medication directly to the lungs.
Additionally, they may be used with a variety of COPD drugs, such as steroids, including Flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand for metered dose inhaler devices, which could increase the metered dose inhaler device market overall.
However, a rise in product launches associated with the metered dose inhaler devices also drives its market growth. Additionally, in May 2025, MediPharm Labs Corp., a pharmaceutical company focused on precision-formulated cannabinoids, announced the commencement of production for its new cannabis metered dose inhalers designed for the European Union and United Kingdom. These inhalers are manufactured to meet global pharmaceutical standards and will be distributed exclusively by Blackpoint Limited, MediPharm's sales and distribution partner in those regions.
Therefore, owing to the above-mentioned factors, the metered dose inhaler category is expected to witness substantial growth in the overall chronic obstructive pulmonary disease treatment devices market during the given forecast period from 2025 to 2032.
North America is expected to dominate the overall chronic obstructive pulmonary disease treatment devices market:
Among all the regions, North America is expected to dominate the chronic obstructive pulmonary disease treatment devices market in the year 2024. The increasing prevalence of chronic obstructive pulmonary disease, along with rising comorbidities like exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and rise in consumption of tobacco among the youth population in the US are acting as a driving growth factors for COPD treatment devices market. Furthermore, the presence of key players in the region is expected to drive the continued expansion and innovation in the market for chronic obstructive pulmonary disease treatment devices during the forecast period from 2025 to 2032.
According to data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 11.6% of U.S. adults aged 18 years or older were cigarette smokers, equating to an estimated 28.8 million individuals. As per the same source, over 16 million US people were affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD among the population.
According to the data from the American Lung Association (2024), more than 34 million people were living in the US with chronic lung diseases like COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which, over time, makes it harder for patients to breathe.
The rising prevalence of smoking-related diseases and chronic respiratory conditions like COPD is driving the demand for advanced treatment devices. As more individuals face difficulties with breathing and lung function, the need for effective, accessible, and innovative therapeutic solutions is growing. Increased awareness of lung health and the availability of improved technologies are further supporting the expansion of the COPD treatment device market.
Also, the presence of key market players in the region is significantly bolstering the market for chronic obstructive pulmonary disease treatment devices. For instance, in June 2024, Verona Pharma plc. announced that the U.S. Food and Drug Administration (FDA) had approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The medication was designed to be administered via a standard jet nebulizer, eliminating the need for high inspiratory flow or precise hand-breath coordination, making it easier for COPD patients to use effectively.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the chronic obstructive pulmonary disease treatment devices market.
Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic, Trudell Medical International, Novartis AG, AstraZeneca, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd, Terumo Corporation, Cipla Inc., Microlife Corporation, Honsun, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Lepu Medical Technology (Beijing) Co., Ltd., and others.
Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Devices Market:
In August 2023, Lupin Pharmaceuticals, Inc., announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. This product is the generic equivalent of Spiriva(R) HandiHaler(R) (Tiotropium Bromide Inhalation Powder, 18 mcg/capsule) by Boehringer Ingelheim Pharmaceuticals, Inc.
In March 2022, Novartis' Sandoz, a Swiss multinational pharmaceutical corporation, acquired UK-based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI), and pre-metered dry powder inhalers (DPI).
In February 2022, Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, announced the launch of HeroTracker(R) Sense, a novel digital respiratory health solution that transformed a standard metered dose inhaler (pMDI) into a smart, connected healthcare device.
In February 2022, Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, announced the launch of HeroTracker(R) Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
Key takeaways from the chronic obstructive pulmonary disease treatment devices market report study
Market size analysis for current chronic obstructive pulmonary disease treatment devices market size (2024), and market forecast over 8 years (2025 to 2032)
Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Various opportunities available for the other competitors in the chronic obstructive pulmonary disease treatment devices market space
What are the top-performing segments in 2024? How these segments will perform in 2032?
Which are the top-performing regions and countries in the current chronic obstructive pulmonary disease treatment devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for the chronic obstructive pulmonary disease treatment devices market growth in the future?
Target audience who can benefit from this chronic obstructive pulmonary disease treatment devices market report study
Chronic obstructive pulmonary disease treatment devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in chronic obstructive pulmonary disease treatment devices
Various end-users who want to know more about the chronic obstructive pulmonary disease treatment devices market and the latest developments in the chronic obstructive pulmonary disease treatment devices market
Frequently Asked Questions for the Chronic Obstructive Pulmonary Disease Treatment Devices Market:
1. What are chronic obstructive pulmonary disease treatment devices?
The chronic obstructive pulmonary disease treatment devices are the medical devices or tools used by a patient to treat the symptoms of chronic obstructive pulmonary disease. The medication to treat COPD is administered through a device, such as inhalers, used to get relief from the symptoms of the disease.
2. What is the market for chronic obstructive pulmonary disease treatment devices?
The chronic obstructive pulmonary disease treatment devices market is estimated to grow at a CAGR of 6.35% during the forecast period from 2025 to 2032.
3. What are the drivers for the chronic obstructive pulmonary disease treatment devices market?
The market for COPD treatment devices is expected to grow significantly due to several key factors. The increasing prevalence of chronic obstructive pulmonary disease, largely driven by aging populations, tobacco smoking, and rising air pollution, is creating a higher demand for effective respiratory support devices. Additionally, growing awareness and screening programs are leading to earlier diagnosis and treatment, further boosting the need for devices such as inhalers, oxygen concentrators, and nebulizers. Key market players are also investing in product development, introducing portable, smart, and user-friendly technologies that enhance patient compliance and enable home-based care, together driving strong growth in the COPD treatment devices market during the forecast period from 2025 to 2032.
4. Who are the key players operating in the chronic obstructive pulmonary disease treatment devices market?
Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic, Trudell Medical International, Novartis AG, AstraZeneca, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd, Terumo Corporation, Cipla Inc., Microlife Corporation, Honsun, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Lepu Medical Technology (Beijing) Co., Ltd., and others.
5. Which region has the highest share in the chronic obstructive pulmonary disease treatment devices market?
Among all the regions, North America is expected to dominate the chronic obstructive pulmonary disease treatment devices market in the year 2024. The increasing prevalence of chronic obstructive pulmonary disease, along with rising comorbidities like exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and a rise in consumption of tobacco among youth population in the US are acting as a driving growth factors for COPD treatment devices market. Furthermore, the presence of key players in the region is expected to drive the continued expansion and innovation in the market for chronic obstructive pulmonary disease treatment devices during the forecast period from 2025 to 2032.
